The AI Scientist: How Certara and NVIDIA Are Automating Drug Discovery

RADNOR, Pa. – July 07, 2026 – In a move that signals a paradigm shift in pharmaceutical research, Certara, a leader in model-informed drug development, has announced a landmark collaboration with tech giant NVIDIA. The partnership will embed NVIDIA's new BioNeMo Agent Toolkit into Certara’s integrated AI platform, effectively creating autonomous 'AI scientists' designed to dramatically accelerate the long and arduous path from lab hypothesis to life-saving medicine.

This isn't just another software upgrade. The collaboration aims to unify Certara's deep well of biosimulation models, regulatory expertise, and proprietary data with NVIDIA's powerful agentic AI frameworks. The goal is audacious: to computationally simulate human biology in ways that could transform how we discover and develop new therapies. While the promise of speed and efficiency is immense, the initiative also brings to the forefront critical questions about responsibility, regulation, and the future role of human scientists in an increasingly automated world.

The Dawn of the Agentic AI Scientist

At the heart of this partnership is the NVIDIA BioNeMo Agent Toolkit. This is not merely a set of algorithms but a sophisticated framework that allows AI to function as an intelligent collaborator. According to NVIDIA, the toolkit turns an AI agent into an autonomous life sciences scientist, granting it access to a vast array of specialized skills. These AI agents can reason over complex biological data, design and run computational experiments, and propose next steps in a research workflow.

Unlike general-purpose AI, BioNeMo provides domain-specific tools for tasks across the entire drug discovery continuum. This includes protein structure prediction, generative chemistry for designing new molecules, genomic analysis, and biomarker discovery. The performance gains are staggering. By leveraging NVIDIA's GPU-accelerated stack, component tools like Parabricks can accelerate genomic analysis by over 10 times, while others can speed up cheminformatics operations by a factor of 3,000. According to one industry analyst, these tools give an AI agent “the skills of a PhD research assistant and the speed of a supercomputer.”

This move from simple automation to 'agentic' reasoning is the key innovation. Instead of just executing pre-programmed tasks, these AI agents can interpret a high-level goal—such as 'find a molecule that binds to a specific protein target'—and independently devise a multi-step plan to achieve it. This is already being adopted across the industry, with over 50 companies and research institutions, including Eli Lilly and platforms like Databricks and Snowflake, integrating the toolkit.

A Strategic Infusion of Intelligence for Certara

For Certara, this collaboration is a calculated leap forward, building directly upon its established strengths. The company is a dominant force in model-informed drug development (MIDD), a field that uses biosimulation and computational modeling to predict a drug's behavior and optimize its development. Its software and expertise are already embedded in the workflows of more than 2,600 biopharmaceutical companies and are trusted by global regulatory agencies.

By integrating NVIDIA's agentic AI, Certara is supercharging its existing platform. The new capabilities will allow its clients to automate and accelerate complex tasks like optimizing a dosing strategy, interrogating a clinical dataset for hidden insights, or assembling vast amounts of data for a regulatory submission. “Agentic AI combined with Certara's world-class scientists, validated models, and data keeps the scientist in the loop while delivering the speed, scale, and reproducibility our clients need,” said Jon Resnick, Certara's Chief Executive Officer.

This 'scientist-in-the-loop' model is a cornerstone of the company's strategy. Rather than replacing human experts, the AI agents are positioned as powerful augmentations, handling the massive computational load and data analysis to free up scientists for higher-level strategic thinking and decision-making. Chris Bouton, Certara's Chief Technology Officer, framed the collaboration as a pivotal step toward a grander vision. “We believe it will become increasingly possible to computationally simulate human biology in ways that will transform the discovery and development of new medicines,” he stated.

Redrawing the Competitive Map in Pharma AI

The Certara-NVIDIA alliance does not exist in a vacuum. It enters a fiercely competitive landscape where billions are being invested in the race to apply AI to drug discovery. Google's Alphabet has launched Isomorphic Labs, which has already inked massive deals with Eli Lilly and Novartis. Companies like Recursion Pharmaceuticals, which also partners with NVIDIA, and BenevolentAI have built their entire business models around AI-driven discovery.

However, the Certara partnership carves out a unique and potentially more impactful niche. While many AI players focus on the early stages of discovery, such as identifying novel drug targets, Certara's expertise spans the full development continuum, right through to regulatory approval. By integrating agentic AI into this end-to-end workflow, the collaboration aims to solve a different, arguably more complex problem: how to generate integrated, regulatory-grade evidence faster and more reliably. This focus on validation and regulatory acceptance, combined with the power of NVIDIA’s platform, could set a new industry standard and create a significant competitive moat.

Beyond the Algorithm: The Mandate for Responsible Innovation

The immense power of agentic AI in medicine comes with a profound responsibility. As these autonomous systems begin to influence decisions that directly impact human health, the need for rigorous validation and ethical oversight becomes paramount. Regulatory bodies like the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) are actively developing frameworks for AI in medicine, focusing on principles like data quality, model transparency, and robust performance monitoring.

The challenges are significant. How do you validate an AI model that is continuously learning? How do you ensure its recommendations are free from the biases embedded in its training data? And how do you maintain accountability when a decision is made by an autonomous agent? There are no easy answers, but Certara's public commitment to keeping the “scientist at the center of decision-making” is a crucial first step. This human oversight is essential not only for catching errors but also for ensuring that the AI's purely computational logic is tempered with the nuanced, ethical judgment that is critical in medicine.

This collaboration is a bold bet that the fusion of human expertise and artificial intelligence will unlock the next great wave of medical breakthroughs. As these AI scientists begin their work inside Certara's platform, the entire industry will be watching to see if they can deliver on their transformative promise responsibly.